BRPI0518571A2 - peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer - Google Patents
peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncerInfo
- Publication number
- BRPI0518571A2 BRPI0518571A2 BRPI0518571-8A BRPI0518571A BRPI0518571A2 BR PI0518571 A2 BRPI0518571 A2 BR PI0518571A2 BR PI0518571 A BRPI0518571 A BR PI0518571A BR PI0518571 A2 BRPI0518571 A2 BR PI0518571A2
- Authority
- BR
- Brazil
- Prior art keywords
- alpha
- cancer vaccine
- peptides
- thymosine
- subject
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title abstract 5
- 238000009566 cancer vaccine Methods 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000012646 vaccine adjuvant Substances 0.000 title abstract 2
- 108010046075 Thymosin Proteins 0.000 abstract 2
- 230000000899 immune system response Effects 0.000 abstract 2
- 102000007501 Thymosin Human genes 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63317504P | 2004-12-06 | 2004-12-06 | |
| PCT/US2005/043985 WO2006062917A2 (en) | 2004-12-06 | 2005-12-06 | Alpha thymosin peptides as cancer vaccine adjuvants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0518571A2 true BRPI0518571A2 (pt) | 2008-11-25 |
Family
ID=36578462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0518571-8A BRPI0518571A2 (pt) | 2004-12-06 | 2005-12-06 | peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100092499A1 (enExample) |
| EP (1) | EP1835931A4 (enExample) |
| JP (1) | JP2008523067A (enExample) |
| KR (1) | KR20070086663A (enExample) |
| CN (1) | CN101072582B (enExample) |
| AU (1) | AU2005314271B2 (enExample) |
| BR (1) | BRPI0518571A2 (enExample) |
| CA (1) | CA2588685A1 (enExample) |
| EA (1) | EA015510B1 (enExample) |
| IL (1) | IL183264A (enExample) |
| MX (1) | MX2007006717A (enExample) |
| NO (1) | NO20072705L (enExample) |
| NZ (1) | NZ555571A (enExample) |
| UA (1) | UA90493C2 (enExample) |
| WO (1) | WO2006062917A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011506467A (ja) * | 2007-12-14 | 2011-03-03 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 |
| JP2012526149A (ja) * | 2009-05-08 | 2012-10-25 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | ワクチン増強剤としてのαチモシンペプチド |
| WO2012109106A1 (en) * | 2011-02-09 | 2012-08-16 | Sciclone Pharmaceuticals, Inc. | Thymosin alpha peptide for preventing, reducing the severity of, and treating infection |
| EP2804626B1 (en) | 2012-01-20 | 2019-05-01 | Fernando Thome Kreutz | Autologous cancer cell vaccine |
| CN104507491A (zh) * | 2012-03-08 | 2015-04-08 | 赛生制药有限公司 | 胸腺素α在治疗化脓性鼻窦炎中的应用 |
| CN107148279B (zh) * | 2014-10-21 | 2021-09-03 | 赛生药品股份国际有限公司 | 用免疫刺激剂治疗癌症 |
| CN107281476B (zh) * | 2017-04-06 | 2020-11-24 | 中国医科大学 | 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用 |
| RU2645957C1 (ru) * | 2017-04-10 | 2018-02-28 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения лучевых повреждений мочевого пузыря |
| RU2663468C1 (ru) * | 2017-09-25 | 2018-08-06 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US653758A (en) * | 1900-03-20 | 1900-07-17 | Austin Gale | Hay-stacking device. |
| DE2604845A1 (de) | 1976-02-07 | 1977-08-18 | Knoll Ag | Neue piperazinderivate |
| JPH0420624A (ja) * | 1990-02-06 | 1992-01-24 | Kanji Yokoe | 勾配側溝施工法及び当該工法に使用する可変側溝 |
| US6537585B1 (en) * | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
| EP1196565A2 (en) * | 1999-06-30 | 2002-04-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| JP2005510491A (ja) * | 2001-10-26 | 2005-04-21 | イミュノ−アールエックス， インコーポレイテッド | 免疫抑制を逆転させるための免疫治療 |
| WO2003035010A2 (en) * | 2001-10-26 | 2003-05-01 | Rhode Island Hospital | Thymosin augmentation of genetic immunization |
| JP2005537246A (ja) | 2002-06-28 | 2005-12-08 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | サイマルファシンを用いて腫瘍抗原発現をアップレギュレートする方法 |
| JP4629033B2 (ja) * | 2003-03-28 | 2011-02-09 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | チモシンα１によるアスペルギルス感染の治療 |
| ES2428358T3 (es) * | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
| JP2012526149A (ja) * | 2009-05-08 | 2012-10-25 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | ワクチン増強剤としてのαチモシンペプチド |
-
2005
- 2005-12-06 WO PCT/US2005/043985 patent/WO2006062917A2/en not_active Ceased
- 2005-12-06 CA CA002588685A patent/CA2588685A1/en not_active Abandoned
- 2005-12-06 AU AU2005314271A patent/AU2005314271B2/en not_active Ceased
- 2005-12-06 JP JP2007545547A patent/JP2008523067A/ja active Pending
- 2005-12-06 EA EA200701166A patent/EA015510B1/ru not_active IP Right Cessation
- 2005-12-06 NZ NZ555571A patent/NZ555571A/en not_active IP Right Cessation
- 2005-12-06 US US11/720,909 patent/US20100092499A1/en not_active Abandoned
- 2005-12-06 EP EP05853022A patent/EP1835931A4/en not_active Withdrawn
- 2005-12-06 UA UAA200707406A patent/UA90493C2/ru unknown
- 2005-12-06 CN CN2005800417998A patent/CN101072582B/zh not_active Expired - Lifetime
- 2005-12-06 KR KR1020077014527A patent/KR20070086663A/ko not_active Ceased
- 2005-12-06 MX MX2007006717A patent/MX2007006717A/es active IP Right Grant
- 2005-12-06 BR BRPI0518571-8A patent/BRPI0518571A2/pt not_active IP Right Cessation
-
2007
- 2007-05-16 IL IL183264A patent/IL183264A/en not_active IP Right Cessation
- 2007-05-29 NO NO20072705A patent/NO20072705L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070086663A (ko) | 2007-08-27 |
| EA015510B1 (ru) | 2011-08-30 |
| CN101072582A (zh) | 2007-11-14 |
| WO2006062917A3 (en) | 2006-11-16 |
| AU2005314271B2 (en) | 2011-06-16 |
| NO20072705L (no) | 2007-09-05 |
| CN101072582B (zh) | 2012-06-27 |
| UA90493C2 (ru) | 2010-05-11 |
| CA2588685A1 (en) | 2006-06-15 |
| EA200701166A1 (ru) | 2008-02-28 |
| EP1835931A2 (en) | 2007-09-26 |
| MX2007006717A (es) | 2007-08-06 |
| IL183264A0 (en) | 2007-09-20 |
| JP2008523067A (ja) | 2008-07-03 |
| WO2006062917A2 (en) | 2006-06-15 |
| US20100092499A1 (en) | 2010-04-15 |
| NZ555571A (en) | 2009-02-28 |
| EP1835931A4 (en) | 2008-12-17 |
| IL183264A (en) | 2010-12-30 |
| AU2005314271A1 (en) | 2006-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012027379A3 (en) | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines | |
| ES2512141T3 (es) | Análogo peptídico de oxintomodulina | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| AU2009326524A8 (en) | Use of Flt3 ligand for strengthening immune responses in RNA immunization | |
| BRPI0905725B8 (pt) | vacina e embalagem farmacêutica | |
| MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| AR054251A1 (es) | Vacuna de toxoide de c. perfringens alfa | |
| BR112016024352A2 (pt) | ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria? | |
| CY1107042T1 (el) | Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων | |
| WO2007103048A3 (en) | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity | |
| EA201170493A1 (ru) | Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот | |
| BRPI0906997A2 (pt) | Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica | |
| EP2228072A4 (en) | CANCER VACCINE COMPOSITION | |
| WO2008098212A3 (en) | Extended release formulations of glucagon and other peptides and proteins | |
| WO2007120673A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| BR112014023572A2 (pt) | método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes | |
| BR112015009541A2 (pt) | novos adjuvantes de mucosa e sistemas de aplicação | |
| BRPI0510430A (pt) | composições e métodos para vacinação mucosal | |
| CL2009001195A1 (es) | Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune. | |
| WO2007079190A3 (en) | Device and method for enhancing immune response by electrical stimulation | |
| AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
| NO20072705L (no) | Alfa-tymosinpeptider som cancervaksineadjuvanser | |
| WO2011053789A3 (en) | Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: BASEADO NO ARTIGO 216 1O DA LPI, PARA QUE A PETICAO NO 20080118249/RJ DE 09/09/2008 SEJA ACEITA, APRESENTE COPIA AUTENTICADA DA PROCURACAO. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |